Tamoxifen increases the risk of microvascular flap complications in patients undergoing microvascular breast reconstruction

Plastic and Reconstructive Surgery

Volumn 129, Issue 2, 2012, Pages 305-314

  Kelley, Brian P ^a   Valero, Vicente ^a   Yi, Min ^a   Kronowitz, Steven J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST RECONSTRUCTION; CHEMICALLY INDUCED DISORDER; FEMALE; HUMAN; METHODOLOGY; MICROVASCULATURE; MIDDLE AGED; PLASTIC SURGERY; POSTOPERATIVE COMPLICATION; RISK; VASCULARIZATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; HUMANS; MAMMAPLASTY; MICROVESSELS; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RISK; SURGICAL FLAPS; TAMOXIFEN; YOUNG ADULT;

EID: 84856743729     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e31823ae86c     Document Type: Article

References (19)

1. Altekruse SF, Kosary CL, Krapacho M, et al. SEER Cancer Statistics Review, 1975-2007. Bethesda, Md.: National Cancer Institute; 2010.
2. Winer EP. Optimizing endocrine therapy for breast cancer. J Clin Oncol. 2005;23:1609-1610.
3. Miller VM, Duckles SP. Vascular actions of estrogens: Functional implications. Pharmacol Rev. 2008;60:210-241.
4. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators-Mechanisms of action and application to clinical practice. N Engl J Med. 2003;348:618-629.
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687-1717.
6. Ragaz J, Coldman A. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. J Clin Oncol. 1998;16:2018-2024.
7. Goldhaber SZ. Tamoxifen: Preventing breast cancer and placing the risk of deep vein thrombosis in perspective. Circulation 2005;111:539-541.
8. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007;99:272-282.
9. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-1388.
10. Hernandez RK, Sorensen HT, Pedersen L, et al. Tamoxifen treatment and risk of deep venous thrombosis and pulmo-nary embolism: A Danish population-based cohort study. Cancer 2009;115:4442-4449.
11. De Pinho Pessoa BB, Menezes Cavalcante BB, Maia MP, et al. Effect of tamoxifen on arterial microvascular anastomosis. Microsurgery 2007;27:286-288.
12. Williams JK, Adams MR, Herrington DM, Clarkson TB. Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol. 1992;20:452-457.
13. Stirone C, Boroujerdi A, Duckles SP, Krause DN. Estrogen receptor activation of phosphoinositide-3 kinase, akt, and nitric oxide signaling in cerebral blood vessels: Rapid and long-term effects. Mol Pharmacol. 2005;67:105-113.
14. Li L, Hisamoto K, Kim KH, et al. Variant estrogen receptorc-Src molecular interdependence and c-Src structural requirements for endothelial NO synthase activation. Proc Natl Acad Sci USA. 2007;104:16468-16473.
15. Miller VM, Mulvagh SL. Sex steroids and endothelial function: Translating basic science to clinical practice. Trends Pharmacol Sci. 2007;28:263-270.
16. Ospina JA, Duckles SP, Kraus DN. 17 β-estradiol decreases vascular tone in cerebral arteries by shifting COX-dependent vasoconstriction to vasodilation.AmJ Physiol Heart Circ Physiol. 2003;285:H241-H250.
17. Sherwood A, Bower JK, McFetridge-Durdle J, et al. Age moderates the short-term effects of transdermal 17 β-estradiol on endothelium-dependent vascular function in postmenopausal women. Arterioscler Thromb Vasc Biol. 2007;27:1782-1787.
18. Haas E, Meyer MR, Schurr U, et al. Differential effects of 17 β-estradiol on function and expression of estrogen receptorα, estrogen receptorβ, and GPR30 in arteries and veins of patients with atherosclerosis. Hypertension 2007;49:1358-1363.
19. Nolvadex. Available at: Http://www.fda.gov/downloads/Drugs/ DrugSafety/ucm088661.pdf. Accessed October 15, 2010.